NEW YORK, Sept. 9 /PRNewswire/ — The Prix Galien USA committee,
responsible for awarding the most prestigious prize in
biopharmaceutical research and development, today announced the
2010 winner of the Pro Bono Humanum Award for the 4th annual Prix
Galien USA Awards competition. The award, recognizing exemplary and
innovative efforts to improve the human condition, will be
presented to UNITAID in partnership with the Clinton Health Access
Initiative (CHAI) for their tremendous work combating the global
HIV/AIDS epidemic.
Philippe Douste-Blazy, M.D., President of UNITAID, and President
William J. Clinton, President of CHAI, will be accepting the award
on behalf of their organizations. UNITAID and CHAI’s efforts to
reduce the price of quality medicines and diagnostics, while
accelerating the pace at which these health products are made
available, have resulted in the distribution of life-saving
medicines to more than 456,000 people in 40 countries.
Elie Wiesel, Nobel Laureate and Prix Galien USA committee
member, will present the award at a black tie ceremony at the
American Museum of Natural History in New York City on September
28, 2010. The Prix Galien USA Pro Bono Humanum Award will accompany
a series of other awards honoring companies who have made
innovative contributions to biopharmaceutical and medical
technology research and development.
“The collaboration between UNITAID and the Clinton Health Access
Initiative truly embodies the spirit of the Pro Bono Award by
moving us forward in improving the human condition, particularly
for those affected by HIV/AIDS. The combination of innovative
financing, philanthropic goals, and effective delivery of medicines
makes this award and citation natural winners for the 2010 Pro Bono
Award,” said Gerald Weissmann, M.D., Prix Galien USA committee
chair, New York University professor emeritus and editor-in-chief
of The FASEB Journal. “Because of this partnership, three
out of four children wi
‘/>”/>
